Celcuity Announced Overall Survival Data From Two Patient Cohorts Evaluated In A Phase 1B Trial With Gedatolisib, A PI3K/mTORC1/2 Inhibitor, In Combination With Palbociclib And Either Letrozole Or Fulvestrant, In Patients With HR+, HER2-advanced Or...

Benzinga07:12 ET

Wall Street Set to Open Flat Thursday; Initial Jobless Claims Higher Than Expected

MT NewswiresDec 5 09:03 ET

Investors Await Jobless Claims Data as Markets Tread Water in Thursday's Premarket

MT NewswiresDec 5 08:13 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Celcuity (CELC)

TipRanksNov 19 02:40 ET · Ratings

A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $27 to $42

Moomoo NewsNov 16 08:00 ET · Ratings

Celcuity Price Target Maintained With a $27.00/Share by HC Wainwright & Co.

Dow JonesNov 15 14:38 ET · Ratings